Randomized Trialhigh evidence
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty.
Cell stem cell·March 5, 2026·PMID 41747733
Why it mattersAging frailty currently lacks effective pharmacologic or biologic therapies, and this trial provides early evidence that a stem cell intervention can meaningfully improve objective physical function in this population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled